You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Cardinal Health raised fiscal 2027 non-GAAP diluted EPS guidance to $12.80 to $13 from $12.40 to $12.60, citing broad-based operating momentum; Q1 revenue rose 5% to $67.5 billion and diluted EPS grew 28% to $3.26.
Cardinal Health raised fiscal 2027 non-GAAP diluted EPS guidance to $12.80 to $13 from $12.40 to $12.60, after first-quarter revenue grew 5% to $67.5 billion and diluted EPS grew 28 percent to $3.26.
For the three months ended September 30, 2026, Cardinal Health, Inc. reported revenue up 5 percent to $67.5 billion, GAAP operating earnings up 13 percent to $753 million, and GAAP diluted EPS up 27 percent to $2.38.
Cardinal Health reported first quarter fiscal year 2027 revenue of $67.5 billion, up 5%, and non-GAAP diluted EPS of $3.26, up 28%. It raised fiscal 2027 non-GAAP EPS guidance to $12.80 to $13.00 from $12.40 to $12.60 and completed a $500 million share repurchase program.
Cardinal Health entered a binding letter of intent to extend its distribution agreement with CVS Health through June 30, 2032, reaffirming fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth ($12.40 to $12.60) and long-term non-GAAP EPS growth guidance of 12% to 14%.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Cardinal Health reported first-quarter revenue, operating earnings and EPS growth, raised fiscal 2027 EPS guidance, and completed a $500 million share repurchase. The main headwinds were a 28% decline in GMPD profit, IRA-related pharma pressure, and petroleum costs pushing GMPD toward the low end of guidance.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Adjusted Free Cash Flow non-GAAP | $4.97B | Fiscal Year 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 5.17B
+45M Repurchases of liability-classified Specialty Alliance Units
-649M Additions to property and equipment
+401M Payments related to matters included in litigation (recoveries)/charges, net
= Non-GAAP Adjusted Free Cash Flow 4.97B
|
|||
| Non-GAAP diluted EPS attributable to Cardinal Health, Inc. non-GAAP | $11.26 | FY26 | — |
| Non-GAAP net earnings attributable to Cardinal Health, Inc. non-GAAP | $2.7B | FY26 | — |
| Non-GAAP operating earnings non-GAAP | $3.6B | FY26 | — |
| Operating cash flow | $5.2B | FY26 | — |
| Share repurchase authorization | $6.4B | as of August 2026 | — |
| Share repurchases | $1.4B | FY26 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CAH
this stock
Cardinal Health Inc
|
$64.97B | +36.8% | +14.2% | — | 3.3% |
|
MCK
Mckesson Corp
|
$127.33B | +34.4% | +3.1% | 28.4 | 1.7% |
|
COR
Cencora, Inc.
|
$68.51B | +6.3% | +9.3% | 26.7 | 1.7% |
|
HSIC
Henry Schein Inc
|
$9.53B | +14.1% | +5.9% | 23.6 | 8.5% |
|
EBOSY
EBOS Group Limited
|
$2.37B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Cardinal Health raised fiscal 2027 non-GAAP diluted EPS guidance to $12.80 to $13 from $12.40 to $12.60, citing broad-based operating momentum; Q1 revenue rose 5% to $67.5 billion and diluted EPS grew 28% to $3.26.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CAH | +3.5% | +10.6% | +40.3% | +12.2% | +36.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +0.9% | +11.8% | +39.8% | +12.4% | +26.2% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
